The following adverse events have been reported from clinical trial and post-marketing experience. (See Table.)
Frequencies are defined as: common (≥1/100, <1/10), uncommon (≥1/1,000, <1/100), rare (≥1/10,000, <1/1,000) and very rare (<1/10,000).
![](https://mpfshstrg.blob.core.windows.net/mpf-uat-common-resources/Images/monograph/table.gif)
There have been post-marketing reports of bone fractures (see Precautions).
View ADR Monitoring Form